This biotech’s stock rockets on oral obesity drug partnership with...
Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments. Source link
Tag: oral
1 results found
https://www.profitableratecpm.com/cznhmu019?key=c35926071f72cfbbd2ab4926dd9618c5
